Imre Corp.Ls Prosorba immune absorption column has beenused to successfully treat a patient with a variant of animmune-related blood clotting disorder, which may prove to bea new indication for the device.

The Prosorba column removes harmful immune componentsfrom the blood and has been approved to treat idiopathicthrombocytopenic purpura, hemorrhaging associated withdecreased platelet counts.

As reported in the March 5 New England Journal of Medicine,the column was used successfully after all other attempts failedat treating a womanLs thrombotic thrombocytopenic purpura.

The Seattle company (NASDAQ:IMRE) is evaluating the rarethrombotic form of the disease as an indication for the column.Its stock closed at $3.81, up 18 cents, on Tuesday. -- RF

(c) 1997 American Health Consultants. All rights reserved.